Bristol-Myers Squibb (NYSE:BMY) Stock Position Reduced by Chicago Capital LLC

Chicago Capital LLC decreased its stake in Bristol-Myers Squibb (NYSE:BMY) by 10.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,262 shares of the biopharmaceutical company’s stock after selling 1,275 shares during the quarter. Chicago Capital LLC’s holdings in Bristol-Myers Squibb were worth $637,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Means Investment CO. Inc. increased its stake in shares of Bristol-Myers Squibb by 2.4% during the 4th quarter. Means Investment CO. Inc. now owns 29,845 shares of the biopharmaceutical company’s stock worth $1,688,000 after purchasing an additional 696 shares during the last quarter. FSM Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $340,000. HHM Wealth Advisors LLC lifted its position in shares of Bristol-Myers Squibb by 21.9% in the fourth quarter. HHM Wealth Advisors LLC now owns 2,866 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 514 shares during the last quarter. Horst & Graben Wealth Management LLC boosted its stake in shares of Bristol-Myers Squibb by 2.4% during the 4th quarter. Horst & Graben Wealth Management LLC now owns 7,538 shares of the biopharmaceutical company’s stock worth $426,000 after acquiring an additional 179 shares in the last quarter. Finally, Valley National Advisers Inc. increased its holdings in shares of Bristol-Myers Squibb by 494.0% during the 4th quarter. Valley National Advisers Inc. now owns 31,848 shares of the biopharmaceutical company’s stock valued at $1,800,000 after acquiring an additional 26,486 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on BMY. Daiwa Capital Markets raised Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Wolfe Research initiated coverage on shares of Bristol-Myers Squibb in a report on Friday, November 15th. They set a “peer perform” rating for the company. UBS Group lifted their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and upped their price target for the company from $63.00 to $70.00 in a report on Monday, December 16th. Finally, TD Cowen lifted their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $56.60.

Bristol-Myers Squibb Stock Up 1.8 %

Shares of BMY opened at $60.03 on Tuesday. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.10. The stock has a market cap of $121.76 billion, a price-to-earnings ratio of -16.72, a P/E/G ratio of 2.10 and a beta of 0.45. The company has a 50-day moving average price of $57.60 and a two-hundred day moving average price of $53.34. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were paid a $0.62 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. This represents a $2.48 annualized dividend and a yield of 4.13%. Bristol-Myers Squibb’s payout ratio is currently -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.